Fraunhofer-Gesellschaft

News

Fraunhofer IME / 15.9.2021

Federal President's Award

Team of Continental, Fraunhofer IME and the University of Münster Nominated for Federal President's Award.

Announcement from the Fraunhofer Senate / 4.8.2021

Term for Fraunhofer President Prof. Reimund Neugebauer extended until 2024

Research data infrastructure / 2.7.2021

NFDI-MatWerk

Materials Science and Engineering institutions collaborate on implementing a distributed research data infrastructure.

Research data infrastructure / 2.7.2021

NFDI4DataScience

GWK decided to fund the NFDI for Data Science and Artificial Intelligence proposal. The consortium is coordinated by the Fraunhofer FOKUS. NFDI4DataScience aims to establish a community-driven research data infrastructure for Data Science and AI. 

 

Fraunhofer lead markets

Our strategic customer segments provide industry customers with access to Fraunhofer’s industry-oriented services.

 

Fraunhofer IOSB / September 01, 2021

Activity detection inside the vehicle

A new system developed by Fraunhofer IOSB is the world’s first to be able to use image data to draw conclusions about the driver’s activity.

 

10.11.2021

Fraunhofer magazine 3.2021

What we're really lacking

Raw materials, supply routes, digital souvereignty

 

Fraunhofer map

Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.

 

Headquarters

Hansastraße 27c
80686 München
Germany
Phone +49 89 1205-0
Fax +49 89 1205-7513 

Latest News

25.11.2021

Coalition agreement between the SPD, the Greens and the FDP

Fraunhofer President Prof. Reimund Neugebauer: “The coalition agreement that has been presented paves the way for Germany to reach technologically-driven and economically-feasible climate neutrality. The new government combines economic, ecological and social goals. This sends important signals for competitiveness, sustainable value creation and technological sovereignty. Artificial intelligence, quantum and hydrogen technologies are key drivers of innovation. Fraunhofer particularly welcomes the commitment to increase Germany’s R&D investment to a GDP share of at least 3.5 percent by 2025. Our 75 Fraunhofer Institutes not only create value locally, but they also generate valuable technological knowledge and expertise for the transfer of ideas to commercial applications. As a reliable partner to industry and society, we look forward to working with the new governing coalition on all current and upcoming challenges.”
Read more

3.11.2021

Stem cells from the bioreactor

With the aid of artificial stem cells, it will soon be possible to establish new treatments for previously incurable diseases such as Alzheimer’s disease. At the Fraunhofer Project Center for Stem Cell Process Engineering SPT, a process for the mass production of these so called induced pluripotent stem cells is being developed. This process involves new materials, which ensure that industrial cell production will meet high quality standards. The process will be unveiled to the public for the first time at the MEDICA trade fair in Düsseldorf, Germany, between November 15 and 18, 2021 (hall 3, stand E74).
Read more

2.11.2021

Safe, patient-friendly implants for personalized therapy

Implants can actively support the body, as in the case of pacemakers, neuro-prostheses or cochlear implants. In the future, active implants will be smaller, less energy-intensive and, above all, more patient-friendly. This is why the Fraunhofer Institute for Biomedical Engineering IBMT is working on miniaturization, external power supplies and wirelessly networked implants. The latest developments will be presented at COMPAMED/MEDICA in Düsseldorf from November 15 to 18 (Hall 13, Stand D60).
Read more

2.11.2021

Fraunhofer Institutes present the first prototype for digital twins of patients

Optimum prevention, diagnosis and treatment in just one click: As part of the “MED²ICIN” lighthouse project, seven Fraunhofer Institutes are presenting the first prototype of a digital patient model. This prototype revolutionizes the very foundation of personalized and cost-optimized treatment, opening up new perspectives. It has already been tested at University Hospital Frankfurt.
Read more